The Tachi Yamada legacy tree continues to grow with a new gene editing biotech from Jim Wilson
Jim Wilson has been busy lately.
Back in May, the AAV pioneer from the University of Pennsylvania launched a second-generation gene therapy biotech, G2 Bio Companies, and just last week unveiled a nonprofit aiming to serve rare disease populations where the pharma model provides little economic incentive. Both efforts saw significant involvement from the late Tachi Yamada, who continues to inspire those working at his legacy startups.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.